The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3201-3206

  Schild, Steven E ^a   Stella, Philip J ^a   Geyer, Susan M ^a   Bonner, James A ^a   McGinnis, William L ^a   Mailliard, James A ^a   Brindle, Jeffery ^a   Jatoi, Aminah ^a   Jett, James R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER STAGING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION PNEUMONIA; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0141465153     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.019     Document Type: Article

References (25)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics 2002. CA Cancer J Clin 52:23-47, 2002
2. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program: SEER Incidence Crude Rates, 11 Registries, 1992-1999. http://www.seer.cancer.gov/faststats/html/inc_lungb.html
3. Perez-Carlos A: Non-small cell carcinoma of the lung: Dose-time parameters. Cancer Treat Symp 2:131-142, 1985
4. Dillman RO, Herndon J, Seagren SL, et al.: Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 88:1210-1215, 1996
5. Komaki R, Scott CB, Sause WT, et al: Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588 - Radiation Therapy Oncology Group Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 39:537-544, 1997
6. Arriagada R, LeChevalier T, Rekacewicz C, et al: Cisplatin-based Chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): Late analysis of a French randomized trial program. Proc Am Soc Clin Oncol 16:446a, 1997 (abstr 1601)
7. Arriagada R, LeChevalier T, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 10:5239-5244, 1994 (suppl 1)
8. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
9. Wang CC: Altered fractionated radiation therapy for head and neck carcinomas: The Massachusetts General Hospital Experience. Ann Acad Med Singapore 25:335-340, 1996
10. Ang KK: Altered fractionation trials in head and neck cancer. Semin Radiat Oncol 8:230-236, 1998
11. Mendenhall WM, Parsons JT: Altered fractionation in radiation therapy for squamous-cell carcinoma of the head and neck. Cancer Invest 16:594-603, 1998
12. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase iii randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
13. Shaw EG, McGinnis WL, Jett JR, et al.: Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant VP16-CDDP chemotherapy in patients with unresectable stage III non-small cell carcinoma of the lung. J Natl Cancer Inst 85:321-323, 1993
14. Schild SE, Stella PJ, Geyer SM, et al: A phase III trial comparing chemotherapy plus either once a day radiotherapy (QD RT) or twice a day radiotherapy (BID RT) in stage III non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 54:370-378, 2002
15. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Soc 53:457-481, 1958
16. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: Analysis and examples. Br J Cancer: 35:1-39, 1977
17. Noordijk EM, vd Poest Clement E, Hermans J, et al: Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 13:83-89, 1988
18. Gauden SJ, Tripcony L: The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 32:71-79, 2001
19. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
20. Komaki R, Seiferheld W, Curran WJ, et al: Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 48:113, 2000 (abstr 5)
21. Langer C, Scott C, Byhardt R, et al: Effect of advanced age on outcome in radiation therapy oncology group studies of locally advanced NSCLC (LA-NSCLC). Lung Cancer 29:104, 2000 (abstr 340)
22. Langer CJ, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer (LA NSCLC) benefit from combined modality therapy, secondary analysis of radiation therapy oncology group (RTOG) 94-10. Proc Am Soc Clin Oncol 21:299a, 2002 (abstr 1193)
23. Rocha Lima CM, Herndon JE, Kosty M, et al: Therapy choices among older patients with lung carcinoma: An evaluation of two trials of the cancer and leukemia group. B Cancer 94:181-187, 2002
24. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
25. Jatoi A, Mailliard JA, Hillman S, et al: Weekly carboplatin and paclitaxel in elderly non-small cell lung cancer patients (≥65 years of age): A phase II North Central Cancer Treatment Group study. J Clin Oncol (in press)